29 Mar 2011 07:00
Proteome Sciences plc ("Proteome Sciences")
Proteome Sciences Closes Further Research Contract with Takeda
29thMarch 2011 Proteome Sciences plc ("Proteome") is pleased to announce that Takeda Pharmaceutical Company Limited ("Takeda") has signed a further contract to use PS Biomarker Services™. PS Biomarker Services™ will provide Takeda with mass spectrometric assays for disease related proteins.
Proteome has a strong track-record in the discovery / validation of peptide and protein biomarkers and will apply its capabilities in assay development for the Takeda contract.
Commenting on the collaboration Christopher Pearce, Chief Executive of Proteome Sciences said:
"PS Biomarker Services™ is ideally placed to undertake biomarker programmes at clinical/ preclinical stages and we are pleased to be working with Takeda on this new project".
Ends
For further information please contact:
Proteome Sciences plc | |
www.proteomics.com | Tel: +44 (0)1932 865065 |
Christopher Pearce, Chief Executive Officer | christopher.pearce@proteomics.com |
James Malthouse, Finance Director | james.malthouse@proteomics.com |
Dr. Ian Pike, Chief Operating Officer Dr. Rainer Voegeli, Commercial Director | ian.pike@proteomics.com rainer.voegeli@proteomics.com
|
Nominated Adviser | |
Singer Capital Markets Limited | Tel: +44 (0)20 3205 7500 |
Shaun Dobson/Claes Spång | |
Public Relations | |
IKON Associates | Redleaf Communications Limited |
Adrian Shaw | Anna Dunkin/Lucy Salaman |
Tel: +44 (0)1483 271291 | Tel: +44 (0)20 7566 6700 |
Mobile: +44 (0)7979 900733 | Email: proteome@redleafpr.com |
Email: adrian@ikonassociates.com | |
Notes to Editors:
About Proteome Sciences
Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows developed on the latest Orbitrap Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.
Visit: http://www.proteomics.com.
Proteome (PRM)